Burrows F J, Thorpe P E
Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas 75235-8576.
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8996-9000. doi: 10.1073/pnas.90.19.8996.
Antibody-based therapy of solid tumors has met with limited success, chiefly because solid tumors are relatively impermeable to macromolecules. This problem could be circumvented by attacking the readily accessible endothelial cells of the tumor vascular bed. We have developed a model to test this "vascular targeting" approach in which cytokine gene transfection of the tumor cells causes them to induce an experimental marker selectively on tumor vascular endothelium. An anti-tumor endothelial cell immunotoxin caused complete occlusion of the tumor vasculature and dramatic regressions of large solid tumors. By contrast, a conventional anti-tumor cell immunotoxin of equivalent in vitro potency produced only minor, transient antitumor effects but, when combined, the two immunotoxins induced permanent complete remissions in over half of the animals. These experiments indicate that immunotoxins directed against recently described markers on vascular endothelial cells in human tumors could provide a general treatment for solid tumors in humans.
基于抗体的实体瘤治疗取得的成功有限,主要原因是实体瘤对大分子相对不通透。通过攻击肿瘤血管床中易于接近的内皮细胞,可以规避这个问题。我们已经开发出一个模型来测试这种“血管靶向”方法,其中肿瘤细胞的细胞因子基因转染使它们在肿瘤血管内皮上选择性地诱导一种实验标记物。一种抗肿瘤内皮细胞免疫毒素导致肿瘤血管完全闭塞,大型实体瘤显著消退。相比之下,一种体外效力相当的传统抗肿瘤细胞免疫毒素仅产生轻微、短暂的抗肿瘤作用,但是,将这两种免疫毒素联合使用时,在超过半数的动物中诱导出永久性完全缓解。这些实验表明,针对人类肿瘤血管内皮细胞上最近描述的标记物的免疫毒素可为人类实体瘤提供一种通用治疗方法。